Conference Coverage

Canagliflozin falls short for primary CV prevention in T2DM

Publish date: February 2, 2018

 

REPORTING FROM THE AHA SCIENTIFIC SESSIONS

SOURCE: Mahaffey KW et al. AHA Scientific Sessions.

Pages

Recommended Reading

Shedding light on shift work’s influence on cardiometabolic risk
MDedge Internal Medicine
Bariatric surgery comes with some risk of complications
MDedge Internal Medicine
Breastfeeding lowers later diabetes risk in women
MDedge Internal Medicine
Insulin delivery devices now covered under Part D
MDedge Internal Medicine
Gastric bypass T2D benefit can fade over time
MDedge Internal Medicine
Listen up: Acoustic device useful for diabetic foot ulcers
MDedge Internal Medicine
New hematologic, cardiovascular system link may have therapeutic implications
MDedge Internal Medicine
How to prioritize CVD reduction in type 2 diabetes
MDedge Internal Medicine
Learn ‘four Ds’ approach to heart failure in diabetes
MDedge Internal Medicine
Three in 10 of your diabetic patients may have liver fibrosis
MDedge Internal Medicine